Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.

[1]  M. Hallek,et al.  The bispecific immunoligand ULBP2‐aCEA redirects natural killer cells to tumor cells and reveals potent anti‐tumor activity against colon carcinoma , 2013, International journal of cancer.

[2]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[3]  D. Chaussabel,et al.  Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. , 2013, Blood.

[4]  S. Gasser,et al.  Regulation of self-ligands for activating natural killer cell receptors , 2013, Annals medicus.

[5]  M. Peipp,et al.  Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype , 2013, Oncoimmunology.

[6]  M. Pranchevicius,et al.  Production of recombinant immunotherapeutics for anticancer treatment , 2013, Bioengineered.

[7]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[8]  J. Koch,et al.  Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. , 2013, Trends in immunology.

[9]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[10]  A. Rothe,et al.  Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Rosanna La Rocca,et al.  Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.

[12]  R. Nibbs,et al.  Suppression, subversion and escape: the role of regulatory T cells in cancer progression , 2013, Clinical and experimental immunology.

[13]  Philippe Bousso,et al.  Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell–Tumor Cell Interactions , 2012, The Journal of Immunology.

[14]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[15]  H. Modjtahedi,et al.  Therapeutic application of monoclonal antibodies in cancer: advances and challenges. , 2012, British medical bulletin.

[16]  P. Parren,et al.  Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity , 2012, The Journal of Immunology.

[17]  C. Turtle,et al.  Engineered T cells for anti-cancer therapy. , 2012, Current opinion in immunology.

[18]  Ming-Ru Wu,et al.  An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo , 2012, The Journal of Immunology.

[19]  T. Greten,et al.  Immune Suppression: The Hallmark of Myeloid Derived Suppressor Cells , 2012, Immunological investigations.

[20]  F. McAleese,et al.  RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. , 2012, Future oncology.

[21]  H. Abken,et al.  CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. , 2012, Trends in molecular medicine.

[22]  K. Curran,et al.  Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions , 2012, The journal of gene medicine.

[23]  Herren Wu,et al.  The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA , 2012, PloS one.

[24]  P. Parren,et al.  Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity , 2012, Leukemia.

[25]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[26]  R. Kontermann.  Dual targeting strategies with bispecific antibodies , 2012, mAbs.

[27]  W. Wels,et al.  NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin , 2012, Journal of cellular and molecular medicine.

[28]  M. Gobbi,et al.  High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. , 2012, Blood.

[29]  L. Weiner,et al.  Monoclonal antibodies for the treatment of cancer. , 2012, Seminars in cancer biology.

[30]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[31]  G. Schackert,et al.  Tumor Evasion from T Cell Surveillance , 2011, Journal of biomedicine & biotechnology.

[32]  H. Kohrt,et al.  Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. , 2011, Trends in immunology.

[33]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[34]  P. Sondel,et al.  Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity , 2011, Journal of biomedicine & biotechnology.

[35]  R. Solana,et al.  NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions , 2011, Journal of Innate Immunity.

[36]  P. Moore,et al.  Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.

[37]  B. Power,et al.  Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma , 2011, Molecular Cancer Therapeutics.

[38]  M. Roberti,et al.  Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications , 2011, Journal of biomedicine & biotechnology.

[39]  D. Saul,et al.  A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting , 2011, mAbs.

[40]  J. Koch,et al.  IL‐2‐activated haploidentical NK cells restore NKG2D‐mediated NK‐cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA , 2010, European journal of immunology.

[41]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Saul,et al.  A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting , 2010, British journal of haematology.

[43]  A. Mackensen,et al.  Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16 , 2010, Journal of immunotherapy.

[44]  A. Mackensen,et al.  Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells , 2010, British journal of haematology.

[45]  T. Wagner,et al.  In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors , 2010, Cancer Gene Therapy.

[46]  J. Passweg,et al.  IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion , 2010, Journal of immunotherapy.

[47]  C. Calfa,et al.  Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. , 2009, Cancer research.

[48]  K. Shitara,et al.  Engineered therapeutic antibodies with improved effector functions , 2009, Cancer science.

[49]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[50]  P. Baeuerle,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[51]  P. Hoffmann,et al.  Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. , 2009, Immunobiology.

[52]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[53]  P. Chames,et al.  Bispecific antibodies for cancer therapy , 2009, Current opinion in drug discovery & development.

[54]  A. Porgador,et al.  Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. , 2009, Journal of proteome research.

[55]  B. Robert,et al.  Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. , 2008, Protein engineering, design & selection : PEDS.

[56]  P. Lang,et al.  A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells , 2008, Journal of immunotherapy.

[57]  A. Engert,et al.  Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function , 2008, PloS one.

[58]  T. Wagner,et al.  Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation , 2008, Gene Therapy.

[59]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[60]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[61]  R. Kontermann,et al.  Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.

[62]  P. Hoffmann,et al.  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. , 2007, Molecular immunology.

[63]  L. Khawli,et al.  H60/TNT-3 Fusion Protein Activates NK Cells In Vitro and Improves Immunotherapeutic Outcome in Murine Syngeneic Tumor Models , 2006, Journal of immunotherapy.

[64]  M. Hallek,et al.  A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. , 2006, Blood.

[65]  B. Robert,et al.  MHC Class I–Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells , 2005, Clinical Cancer Research.

[66]  J. Becker,et al.  DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  L. Moretta,et al.  NK-dependent DC maturation is mediated by TNFα and IFNγ released upon engagement of the NKp30 triggering receptor , 2005 .

[68]  F. Colucci,et al.  Anatomy of a murder--signal transduction pathways leading to activation of natural killer cells. , 2005, Immunology letters.

[69]  P. Kuppen,et al.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. , 2003, Trends in immunology.

[70]  P. Morel,et al.  Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function 1 , 2003, The Journal of Immunology.

[71]  L. Moretta,et al.  Selective cross‐talk among natural cytotoxicity receptors in human natural killer cells , 2003, European journal of immunology.

[72]  S. Ferrone,et al.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.

[73]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[74]  A. Moretta,et al.  Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines , 2000, Journal of Neuroimmunology.

[75]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[76]  M. Little,et al.  Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. , 1999, Journal of molecular biology.

[77]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[78]  M. Pfreundschuh,et al.  Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. , 1997, Blood.

[79]  M. Bevan,et al.  Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[81]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.